Merck’s Cordaptive shows less flushing than Niaspan in Phase III study
The double-blind, randomized, parallel, 16-week study of 1,455 patients with dyslipidemia evaluated flushing symptoms. Across the 16-week treatment period, patients on Cordaptive reported significantly less flushing as measured
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.